Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03493828 · ClinicalTrials.gov registry record · Phase 3
Efficacy of TAP Block in Cesarean Section Patients
A Phase 3 study of Pain Control, sponsored by New York Presbyterian Brooklyn Methodist Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03493828 is a Phase 3 study of Pain Control that has completed, run by New York Presbyterian Brooklyn Methodist Hospital. The registered enrollment target is 60 participants, above the 32-participant average among 3 other Pain Control trials with a reported enrollment target (88% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03493828, a Phase 3 study of Pain Control, has completed, sponsored by New York Presbyterian Brooklyn Methodist Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
TAP Block done with 2 different concentrations of bupivacaine and placebo
Conditions Studied
Interventions
- PROCEDURE TAP block using Bupivacaine 0.5%
- PROCEDURE TAP block using Bupivacaine 0.25%
- PROCEDURE TAP block using Normal Saline
Study Locations (1)
New York
- New York Methodist Hospital - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03493828
The ClinicalTrials.gov registry entry for NCT03493828 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 32-participant average among 3 other Pain Control trials with a reported enrollment target (88% higher). The listed sponsor is New York Presbyterian Brooklyn Methodist Hospital, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pain Control appearing as the primary indexed condition, and to 3 interventions - of which TAP block using Bupivacaine 0.5% is the first listed.
NCT03493828 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03493828 about?
NCT03493828 is a clinical study titled "Efficacy of TAP Block in Cesarean Section Patients". TAP Block done with 2 different concentrations of bupivacaine and placebo
What is the current status of trial NCT03493828?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2013-06. Estimated completion is 2013-12.
What conditions does trial NCT03493828 study?
This clinical trial studies the following conditions: Pain Control.
What interventions are being tested in trial NCT03493828?
The interventions under investigation include: TAP block using Bupivacaine 0.5% (PROCEDURE), TAP block using Bupivacaine 0.25% (PROCEDURE), TAP block using Normal Saline (PROCEDURE).
Who is sponsoring clinical trial NCT03493828?
This trial is sponsored by New York Presbyterian Brooklyn Methodist Hospital, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03493828 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain Control
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.